Back to Research Hub
Enliven Therapeutics, Inc.
ELVN
$36.11+2.48 (+7.37%)
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
StreetsValue research for Enliven Therapeutics, Inc. (ELVN)
Members get the full report for Enliven Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.